150 related articles for article (PubMed ID: 12858351)
1. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors.
Leuschner C; Enright FM; Gawronska-Kozak B; Hansel W
Prostate; 2003 Sep; 56(4):239-49. PubMed ID: 12858351
[TBL] [Abstract][Full Text] [Related]
2. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo.
Gawronska B; Leuschner C; Enright FM; Hansel W
Gynecol Oncol; 2002 Apr; 85(1):45-52. PubMed ID: 11925119
[TBL] [Abstract][Full Text] [Related]
3. Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases.
Hansel W; Leuschner C; Enright F
Mol Cell Endocrinol; 2007 Apr; 269(1-2):26-33. PubMed ID: 17382461
[TBL] [Abstract][Full Text] [Related]
4. Targeting breast and prostate cancers through their hormone receptors.
Leuschner C; Hansel W
Biol Reprod; 2005 Nov; 73(5):860-5. PubMed ID: 16033998
[TBL] [Abstract][Full Text] [Related]
5. Targeted destruction of prostate cancer cells and xenografts by lytic peptide-betaLH conjugates.
Hansel W; Leuschner C; Gawrońska B; Enright F
Reprod Biol; 2001 Jul; 1(1):20-32. PubMed ID: 14666172
[TBL] [Abstract][Full Text] [Related]
6. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo.
Leuschner C; Enright FM; Gawronska B; Hansel W
Breast Cancer Res Treat; 2003 Mar; 78(1):17-27. PubMed ID: 12611453
[TBL] [Abstract][Full Text] [Related]
7. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo.
Hansel W; Enright F; Leuschner C
Mol Cell Endocrinol; 2007 Jan; 260-262():183-9. PubMed ID: 17101210
[TBL] [Abstract][Full Text] [Related]
8. Targeted destruction of normal and cancer cells through lutropin/choriogonadotropin receptors using Hecate-betaCG conjugate.
Zaleska M; Bodek G; Jana B; Hansel W; Ziecik AJ
Exp Clin Endocrinol Diabetes; 2003 May; 111(3):146-53. PubMed ID: 12784188
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for adrenocortical tumors in transgenic mice through their LH receptor by Hecate-human chorionic gonadotropin beta conjugate.
Vuorenoja S; Rivero-Müller A; Ziecik AJ; Huhtaniemi I; Toppari J; Rahman NA
Endocr Relat Cancer; 2008 Jun; 15(2):635-48. PubMed ID: 18509010
[TBL] [Abstract][Full Text] [Related]
11. Targeted destruction of androgen-sensitive and -insensitive prostate cancer cells and xenografts through luteinizing hormone receptors.
Leuschner C; Enright FM; Melrose PA; Hansel W
Prostate; 2001 Feb; 46(2):116-25. PubMed ID: 11170139
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
[TBL] [Abstract][Full Text] [Related]
14. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
[TBL] [Abstract][Full Text] [Related]
15. Hecate-CGbeta conjugate and gonadotropin suppression shows two distinct mechanisms of action in the treatment of adrenocortical tumors in transgenic mice expressing Simian Virus 40 T antigen under inhibin-alpha promoter.
Vuorenoja S; Mohanty BP; Arola J; Huhtaniemi I; Toppari J; Rahman NA
Endocr Relat Cancer; 2009 Jun; 16(2):549-64. PubMed ID: 19261682
[TBL] [Abstract][Full Text] [Related]
16. Use of hecate-chorionic gonadotropin beta conjugate in therapy of lutenizing hormone receptor expressing gonadal somatic cell tumors.
Rivero-Müller A; Vuorenoja S; Tuominen M; Wacławik A; Brokken LJ; Ziecik AJ; Huhtaniemi I; Rahman NA
Mol Cell Endocrinol; 2007 Apr; 269(1-2):17-25. PubMed ID: 17363137
[TBL] [Abstract][Full Text] [Related]
17. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
[TBL] [Abstract][Full Text] [Related]
18. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Bajo AM; Schally AV; Halmos G; Nagy A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
[TBL] [Abstract][Full Text] [Related]
19. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
[TBL] [Abstract][Full Text] [Related]
20. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Westphal G; Halmos G; Engel JB
Cancer Res; 2005 Jul; 65(13):5857-63. PubMed ID: 15994963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
